Diabetic Ketoacidosis Approved Drugs
These are drugs that have been approved by the US Food and Drug Administration (FDA), meaning they have been determined to be safe and effective for use in Diabetic Ketoacidosis.
Found 11 Approved Drugs for Diabetic Ketoacidosis
MetFORMIN
Brand Names
Glyburide-MetFORMIN, Janumet, Saxagliptin, Zituvimet, Invokamet, Pioglitazole, Sitagliptin, Segluromet, Actoplus, Riomet, Glumetza, Jentadueto, Xigduo, MetFORMIN Hydrochoride, Pioglitazone, Trijardy, Alogliptin, Kombiglyze, Dapagliflozin, Glipizide, Glyburide, Synjardy, Kazano
MetFORMIN
Brand Names
Glyburide-MetFORMIN, Janumet, Saxagliptin, Zituvimet, Invokamet, Pioglitazole, Sitagliptin, Segluromet, Actoplus, Riomet, Glumetza, Jentadueto, Xigduo, MetFORMIN Hydrochoride, Pioglitazone, Trijardy, Alogliptin, Kombiglyze, Dapagliflozin, Glipizide, Glyburide, Synjardy, Kazano
Form: Tablet, Solution
Method of administration: Oral
FDA approval date: January 24, 2002
Classification: Dipeptidyl Peptidase 4 Inhibitor
Metformin hydrochloride extended-release tablets, USP are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Metformin hydrochloride is a biguanide indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ( 1 )
Empagliflozin
Brand Names
Jardiance, Glyxambi
Empagliflozin
Brand Names
Jardiance, Glyxambi
Form: Tablet
Method of administration: Oral
FDA approval date: August 01, 2014
Classification: Sodium-Glucose Cotransporter 2 Inhibitor
JARDIANCE is indicated: as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. to reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease. to reduce the risk of cardiovascular death plus hospitalization for heart failure in adults with heart failure and reduced ejection fraction. JARDIANCE is a sodium-glucose co-transporter 2 (SGLT2) inhibitor indicated: as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. ( 1 ) to reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease. ( 1 ) to reduce the risk of cardiovascular death plus hospitalization for heart failure in adults with heart failure and reduced ejection fraction. ( 1 ) Limitations of Use: Not recommended in patients with type 1 diabetes mellitus. It may increase the risk of diabetic ketoacidosis in these patients ( 1 ) Not recommended for use to improve glycemic control in adults with type 2 diabetes mellitus with an eGFR less than 30 mL/min.
Glargine
Brand Names
Toujeo, Lantus Solostar, Semglee, Basaglar, Glargine U-300, Rezvoglar, Lantus, Glargine Solostar
Glargine
Brand Names
Toujeo, Lantus Solostar, Semglee, Basaglar, Glargine U-300, Rezvoglar, Lantus, Glargine Solostar
Form: Injection
Method of administration: Subcutaneous
FDA approval date: September 23, 2009
Classification: Insulin Analog
Insulin glargine is indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus. Insulin glargine is a long-acting human insulin analog indicated to improve glycemic control in adults and pediatric patients with type 1 diabetes mellitus and in adults with type 2 diabetes mellitus. ( 1 ) Limitations of Use Not recommended for treating diabetic ketoacidosis. ( 1 ) Limitations of Use Insulin glargine is not recommended for the treatment of diabetic ketoacidosis.
Levemir
Generic Name
Detemir
Levemir
Generic Name
Detemir
Form: Injection
Method of administration: Subcutaneous
FDA approval date: March 27, 2006
Classification: Insulin Analog
LEVEMIR is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus. Limitations of Use LEVEMIR is not recommended for the treatment of diabetic ketoacidosis. LEVEMIR is a long-acting human insulin analog indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus ( 1 ). Limitations of Use: Not recommended for the treatment of diabetic ketoacidosis.
Tresiba
Generic Name
Degludec
Tresiba
Generic Name
Degludec
Form: Injection
Method of administration: Subcutaneous
FDA approval date: September 25, 2015
Classification: Insulin Analog
Insulin Degludec is indicated to improve glycemic control in patients 1 year of age and older with diabetes mellitus. Limitations of Use Not recommended for the treatment of diabetic ketoacidosis. Insulin Degludec is a long-acting human insulin analog indicated to improve glycemic control in patients 1 year of age and older with diabetes mellitus ( 1 ). Limitations of Use:, Not recommended for the treatment of diabetic ketoacidosis.
Showing 1-5 of 11
Not sure about your diagnosis?
Check Your Symptoms
Tired of the same old research?
Check Latest Advances